To further explore the potential benefits of oats, Dioum et al. conducted a secondary analysis of the serum samples from the trial participants.1 They investigated the effects of the oat product on a novel metric for SCI called Inflammatory Age® (iAge®), derived from the Stanford 1000 Immunomes Project.1 The iAge® predicts multimorbidity, frailty, immune decline, premature cardiovascular aging, and all-cause mortality on a personalized level.1 The researchers found that the oat product had a beneficial effect on subjects with elevated levels of iAge® at baseline (>49.6 iAge® years) as early as two weeks post-treatment.1 In contrast, the rice control group did not show any significant change in iAge®.1 Interestingly, the effects of the oat product on iAge® were largely driven by a decrease in the Eotaxin-1 protein, an aging-related chemokine, independent of a person's gender, body mass index, or chronological age.1